Zoetis Inc. (NYSE:ZTS) Shares Sold by Investment Advisory Services Inc. TX ADV

Investment Advisory Services Inc. TX ADV decreased its position in Zoetis Inc. (NYSE:ZTS) by 2.0% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,623 shares of the company’s stock after selling 132 shares during the quarter. Investment Advisory Services Inc. TX ADV’s holdings in Zoetis were worth $1,090,000 at the end of the most recent quarter.

A number of other hedge funds also recently made changes to their positions in ZTS. KPP Advisory Services LLC lifted its holdings in Zoetis by 17.1% in the 1st quarter. KPP Advisory Services LLC now owns 6,646 shares of the company’s stock worth $1,094,000 after buying an additional 970 shares in the last quarter. Value Partners Investments Inc. lifted its stake in shares of Zoetis by 8.0% in the first quarter. Value Partners Investments Inc. now owns 13,408 shares of the company’s stock worth $2,209,000 after acquiring an additional 994 shares in the last quarter. Kavar Capital Partners Group LLC boosted its holdings in Zoetis by 6.5% in the first quarter. Kavar Capital Partners Group LLC now owns 10,940 shares of the company’s stock valued at $1,801,000 after purchasing an additional 672 shares during the last quarter. Security National Bank boosted its holdings in Zoetis by 4.5% in the first quarter. Security National Bank now owns 50,040 shares of the company’s stock valued at $8,239,000 after purchasing an additional 2,145 shares during the last quarter. Finally, Phillips Wealth Planners LLC acquired a new stake in Zoetis during the 1st quarter valued at approximately $247,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Insider Buying and Selling at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of Zoetis stock in a transaction on Tuesday, June 3rd. The stock was sold at an average price of $170.00, for a total transaction of $110,840.00. Following the sale, the executive vice president now owns 15,129 shares of the company’s stock, valued at $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.18% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several equities analysts have recently commented on ZTS shares. UBS Group reduced their target price on Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research note on Wednesday, May 7th. Piper Sandler upped their price target on shares of Zoetis from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Monday, May 12th. Stifel Nicolaus lowered shares of Zoetis from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $165.00 to $160.00 in a report on Wednesday, June 18th. Finally, Wall Street Zen upgraded shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, March 7th. Two research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Zoetis currently has an average rating of “Buy” and an average target price of $212.13.

Zoetis Price Performance

ZTS opened at $157.41 on Thursday. The company has a quick ratio of 1.04, a current ratio of 1.74 and a debt-to-equity ratio of 1.12. The company’s 50-day moving average price is $160.10 and its 200 day moving average price is $163.02. Zoetis Inc. has a fifty-two week low of $139.70 and a fifty-two week high of $200.33. The firm has a market cap of $70.08 billion, a price-to-earnings ratio of 28.26, a price-to-earnings-growth ratio of 2.62 and a beta of 0.94.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.40 by $0.08. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a return on equity of 55.48% and a net margin of 27.12%. The business’s revenue was up 1.4% on a year-over-year basis. During the same quarter last year, the business posted $1.38 EPS. As a group, sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Investors of record on Friday, July 18th will be given a $0.50 dividend. The ex-dividend date is Friday, July 18th. This represents a $2.00 annualized dividend and a yield of 1.27%. Zoetis’s dividend payout ratio is presently 35.91%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.